MOLECULAR CYTOGENETICS OF SOLID TUMORS

这个医生科学家奖将使弗莱彻博士获得广泛的 在实验细胞遗传学领域的全面培训， 分子生物学 在每个阶段的奖励，这些技能将是 应用于肿瘤学领域的特定研究问题。 一期 将在Cynthia C.莫顿和 菲利普莱德，在病理学和遗传学系，分别在 哈佛医学院。 此阶段的主要重点是本地化 痣样基底细胞癌综合征的致病基因 在阶段 我，弗莱彻博士也将参加在哈佛的研讨会和课程 医学院和杰克逊实验室，并将继续广泛 正在进行的实体瘤细胞遗传学研究。 实体瘤细胞遗传学 项目将包括：1）特征染色体的鉴定 在特定的恶性肿瘤重排; 2）调查的诊断 间叶性肿瘤中特异性细胞遗传学模式的意义;和3） 确定成人遗传不稳定性的程度和作用 恶性肿瘤。 博士Samuel E.勒克斯，血液肿瘤科主任， 波士顿儿童医院，和Steven J. Burakoff博士， Dana-Fraber癌症研究所的儿科肿瘤学将共同赞助II期 这个奖项。 在第二阶段，弗莱彻博士将建立一个实验室 致力于实体瘤的细胞遗传学和分子特征 在丹娜-法伯癌症研究所 该实验室将利用 细胞遗传学结果作为后续分子研究的基础 实体瘤的病因学

This physician-Scientist Award will enable Dr. Fletcher to acquire a broad and thorough training in the fields of experimental cytogenetics and molecular biology. In each phase of the award, these skills will be applied to specific research questions in the field of oncology. Phase I will be conducted under the co-sponsorship of Drs. Cynthia C. Morton and Philip Leder, in the Department of Pathology and Genetics, respectively, at Harvard Medial School. A primary focus of this phase will be to localize the causative gene for nevoid basal cell carcinoma syndrome. During Phase I, Dr. Fletcher will also participate in seminars and courses at Harvard Medical School and at the Jackson Laboratory, and will continue extensive work-in-progress on solid tumor cytogenetics. The solid tumor cytogenetics projects will include: 1) identification of characteristic chromosome rearrangements in specific malignancies; 2) investigation of the diagnostic significance of specific cytogenetic patterns in mesenchymal tumors; and 3) determination of the extent and role of genetic instability in adult malignancies. Dr. Samuel E. Lux, Chief of the Hematology-Oncology Division at The Children's Hospital, Boston, and Dr. STeven J. Burakoff, Chief, Division of Pediatric Oncology, Dana-Fraber Cancer Institute, will co-sponsor Phase II of this award. During Phase II, Dr. Fletcher will establish a laboratory devoted to the cytogenetic and molecular characterization of solid tumors at the Dana-Farber Cancer Institute. This laboratory will utilize cytogenetic findings as a basis for subsequent molecular investigations into the etiologies of solid tumors.